EPO Patents = 3

Forward Citations = 1

Loading Chart...

8 inventors (with patents filed for the assignee):

Eugene Alexander Zhukovsky (4 out of 10 patents)

Richard J Morse (3 out of 3 patents)

Olivier Leger (3 out of 3 patents)

4. Olivier Leger (2 out of 21 patents)

5. Christel Larbouret (1 out of 9 patents)

6. Andre Pelegrin (1 out of 9 patents)

7. Pierre-emmanuel Gerard (1 out of 1 patent)

8. Eugene Zhukovsky (1 out of 1 patent)

9. André Pelegrin (7 patents)

10. Richard J Morse (0 patent)

5 patents: Sort by Forward Citations

1. 12528877 - BINDING MOLECULES TO CD38 AND PD-L1 (2026-01-20),

2. 12054550 - Bispecific antibodies targeting EGFR and HER2 (2024-08-06),

3. 11958913 - Polypeptide linker for preparing multispecific antibodies (2024-04-16),

4. 11560437 - Stable multispecific antibodies (2023-01-24),

5. 11505616 - Binding molecules to CD38 and PD-L1 (2022-11-22),

Company Overview

Biomunex Pharmaceuticals is a biotechnology company focused on developing next-generation antibody-based therapeutics for the treatment of various diseases. The company's innovative platform allows for the rapid discovery and optimization of highly potent antibodies with improved properties and reduced side effects. Biomunex is committed to advancing the field of antibody therapeutics and improving the lives of patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

5 Patents

#568 in Paris

#2,865 in France

Paris, France

Biomunex Pharmaceuticals

Forward Citations = 1

8 inventors:

Eugene Alexander Zhukovsky (4 out of 10 patents)

Richard J Morse (3 out of 3 patents)

Olivier Leger (3 out of 3 patents)

4. Olivier Leger (2 out of 21 patents)

5. Christel Larbouret (1 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Biomunex Pharmaceuticals. Retrieved from https://idiyas.com/company/biomunex-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]